KBIO COMPANY Inc. Logo

KBIO COMPANY Inc.

Using a plant-based platform to rapidly develop biologics for public health.

038530 | KO

Overview

Corporate Details

ISIN(s):
KR7038530002
LEI:
Country:
South Korea
Address:
서울특별시 강동구 올림픽로 834 206호(암사동, 한강시티라이프), 강동구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KBio is a biotechnology company that develops and manufactures biologics using its proprietary plant-based platform, RP3. The company leverages plants as efficient biofoundries to produce high-quality proteins, therapeutics, and bioactive compounds at scale. This innovative and sustainable approach is designed to accelerate research, development, and production timelines, surpassing the limitations of traditional manufacturing methods. KBio's platform aims to address public health challenges by enabling the rapid, large-scale production of novel biomolecules and treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.0 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.7 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 486.5 KB
2025-03-11 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.8 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.1 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 181.2 KB
2025-03-07 00:00
Share Issue/Capital Change
감자결정(종속회사의주요경영사항)
Korean 15.6 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.3 MB
2024-10-18 00:00
Capital/Financing Update
기타경영사항(자율공시) (자기사채(제26회차 전환사채) 소각 결정의 건)
Korean 5.0 KB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 1.4 MB
2024-06-14 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB

Automate Your Workflow. Get a real-time feed of all KBIO COMPANY Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KBIO COMPANY Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KBIO COMPANY Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

HLB INC. Logo
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea
028300
HLB Life Science CO.,LTD. Logo
Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.
South Korea
067630
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea
046210
HLB Pep Co., Ltd. Logo
Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.
South Korea
196300
HLB PHARMACEUTICAL CO., LTD. Logo
Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.
South Korea
047920
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea
343090
H. Lundbeck A Logo
Develops and commercializes innovative therapeutics for brain diseases globally.
Denmark
HLUN
Hoth Therapeutics, Inc. Logo
Advancing therapeutics for metabolic, dermatologic, and inflammatory diseases.
United States of America
HOTH
Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.
South Korea
145020
Humacyte, Inc. Logo
Bioengineering off-the-shelf human tissues for vascular repair and regenerative medicine.
United States of America
HUMA

Talk to a Data Expert

Have a question? We'll get back to you promptly.